Sabine M Oishi1, Nell Marshall1, Alison B Hamilton1,2, Elizabeth M Yano1,3, Barbara Lerner4, Maren T Scheuner1,5,6. 1. Veterans Affairs Health Services Research and Development Center for the Study of Healthcare Innovation, Implementation and Policy, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA. 2. Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA. 3. Department of Health Policy and Management, University of California, Los Angeles, Fielding School of Public Health, Los Angeles, California, USA. 4. Veterans Affairs Health Services Research and Development Center for Healthcare Organization and Implementation Research, Veterans Affairs Boston Healthcare System, Boston, Massachusetts, USA. 5. Division of Medical Genetics, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California, USA. 6. Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Abstract
PURPOSE: Adoption and implementation of evidence-based genetic and genomic medicine have been slow. We describe a methodology for identifying the influence of organizational factors on adoption and implementation of these services in health-care organizations. METHODS: We illustrate a three-component, mixed-methods health services research approach, including expert panels, qualitative interviews with key informants, and quantitative surveys completed by key informants. RESULTS: This research approach yielded a baseline assessment of existing genetic health-care models in the Veterans Health Administration and identified organizational barriers to and facilitators of adoption. In aggregate, the panel and key informant strategies created a communication network of relevant organizational stakeholders and a detailed foundation of organizational knowledge from which to design tools and models for implementation-level genetic/genomic translation. CONCLUSION: Expert panel and key informant strategies can be used to create a backdrop of stakeholder involvement and baseline organizational knowledge within which to plan translation research and to inform strategic planning and policies for adoption and implementation of genetic services in health-care organizations.
PURPOSE: Adoption and implementation of evidence-based genetic and genomic medicine have been slow. We describe a methodology for identifying the influence of organizational factors on adoption and implementation of these services in health-care organizations. METHODS: We illustrate a three-component, mixed-methods health services research approach, including expert panels, qualitative interviews with key informants, and quantitative surveys completed by key informants. RESULTS: This research approach yielded a baseline assessment of existing genetic health-care models in the Veterans Health Administration and identified organizational barriers to and facilitators of adoption. In aggregate, the panel and key informant strategies created a communication network of relevant organizational stakeholders and a detailed foundation of organizational knowledge from which to design tools and models for implementation-level genetic/genomic translation. CONCLUSION: Expert panel and key informant strategies can be used to create a backdrop of stakeholder involvement and baseline organizational knowledge within which to plan translation research and to inform strategic planning and policies for adoption and implementation of genetic services in health-care organizations.
Authors: Alex T Ramsey; Li-Shiun Chen; Sarah M Hartz; Nancy L Saccone; Sherri L Fisher; Enola K Proctor; Laura J Bierut Journal: Transl Behav Med Date: 2018-01-29 Impact factor: 3.046
Authors: Nikki R Wooten; Abbas S Tavakoli; Marlene B Al-Barwani; Naomi A Thomas; Hrishikesh Chakraborty; Anna M Scheyett; Kelly M Kaminski; Alyssia C Woods; Sue E Levkoff Journal: Am J Drug Alcohol Abuse Date: 2017-04-14 Impact factor: 3.829
Authors: Maren T Scheuner; Michael P Douglas; Paloma Sales; Sara L Ackerman; Kathryn A Phillips Journal: Genet Med Date: 2021-05-06 Impact factor: 8.822